October 2019

ORPHELIA Pharma and Veriton Pharma execute a license and distribution agreement for Kigabeq® in the United Kingdom

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer

First-in-class immune checkpoint inhibitor to be presented at SITC

ORPHELIA announces that the CHMP has adopted a positive opinion for Ivozall®

Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

Baikowski® hereby confirms its acquisition of Mathym SAS, a company with which it commenced negotiations in July 2019